Key result
AI promises streamlined cardiovascular trial operations, but requires safeguards against bias, inaccuracy, and privacy risks.
Answers are grounded in this paper and cite their sources.
AI has the potential to streamline cardiovascular clinical trials but must be integrated carefully and transparently to protect the validity of trial results.
Randomized clinical trials are the gold standard for establishing the efficacy and safety of cardiovascular therapies. However, current pivotal trials are expensive, lengthy, and insufficiently diverse. Emerging artificial intelligence (AI) technologies can potentially automate and streamline clinical trial operations. This review describes opportunities to integrate AI throughout a trial's life cycle, including designing the trial, identifying eligible patients, obtaining informed consent, ascertaining physiological and clinical event outcomes, interpreting imaging, and analyzing or disseminating the results. Nevertheless, AI poses risks, including generating inaccurate results, amplifying biases against underrepresented groups, and violating patient privacy. Medical journals and regulators are developing new frameworks to evaluate AI research tools and the data they generate. Given the high-stakes role of randomized trials in medical decision making, AI must be integrated carefully and transparently to protect the validity of trial results.
No takes yet. Share an insight, caveat, or question.
Cunningham et al. (2024) conducted a review in Cardiovascular disease. Artificial intelligence was evaluated. Artificial intelligence technologies can potentially automate and streamline cardiovascular clinical trial operations, but must be integrated carefully to avoid inaccuracies, biases, and privacy violations.
Synapse has enriched 10 related papers. Consider them for comparative context: